Abstract:Background: Antibiotic resistance (ABR) poses a major burden to global health and economic systems. ABR in community-acquired urinary tract infections (CA-UTIs) has become increasingly prevalent. Accurate estimates of ABR's clinical and economic burden are needed to support medical resource prioritization and cost-effectiveness evaluations of urinary tract infection (UTI) interventions. Objective: This study aims to systematically synthesize the evidence on the economic costs associated with ABR in CA-UTIs, using published studies comparing the costs of antibiotic-susceptible and antibiotic-resistant cases. Methods: We searched the PubMed, Ovid MEDLINE and Embase, Cochrane Review Library, and Scopus databases. Studies published in English from January 1, 2008, to January 31, 2023, reporting the economic costs of ABR in CA-UTI of any microbe were included. Independent screening of titles/abstracts and full texts was performed based on prespecified criteria. A quality assessment was performed using the Integrated Quality Criteria for Review of Multiple Study Designs (ICROMS) tool. Data in UTI diagnosis criteria, patient characteristics, perspectives, resource costs, and patient and health economic outcomes, including mortality, hospital length of stay (LOS), and costs, were extracted and analyzed. Monetary costs were converted into 2023 US dollars. Results: This review included 15 studies with a total of 57,251 CA-UTI cases. All studies were from high- or upper-middle-income countries. A total of 14 (93%) studies took a health system perspective, 13 (87%) focused on hospitalized patients, and 14 (93%) reported UTI pathogens. Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa are the most prevalent organisms. A total of 12 (80%) studies reported mortality, of which, 7 reported increased mortality in the ABR group. Random effects meta-analyses estimated an odds ratio of 1.50 (95% CI 1.29-1.74) in the ABR CA-UTI cases. All 13 hospital-based studies reported LOS, of which, 11 reported significantly higher LOS in the ABR group. The meta-analysis of the reported median LOS estimated a pooled excess LOS ranging from 1.50 days (95% CI 0.71-4.00) to 2.00 days (95% CI 0.85-3.15). The meta-analysis of the reported mean LOS estimated a pooled excess LOS of 2.45 days (95% CI 0.51-4.39). A total of 8 (53%) studies reported costs in monetary terms-none discounted the costs. All 8 studies reported higher medical costs spent treating patients with ABR CA-UTI in hospitals. The highest excess cost was observed in UTIs caused by carbapenem-resistant Enterobacterales. No meta-analysis was performed for monetary costs due to heterogeneity. Conclusions: ABR was attributed to increased mortality, hospital LOS, and economic costs among patients with CA-UTI. The findings of this review highlighted the scarcity of research in this area, particularly in patient morbidity and chronic sequelae and costs incurred in community health care. Future research calls for a cost-of-illness analysis of infections, standardizing therapy-pathogen combination comparators, medical resources, productivity loss, intangible costs to be captured, and data from community sectors and low-resource settings and countries.

The Clinical and Economic Impact of Antibiotic Resistance in China: A Systematic Review and Meta-Analysis

Economic Burden of Antibiotic Resistance in ESKAPE Organisms: a Systematic Review

OP115 Effect of Multiple Drug Resistance on Costs for Patients with Intra-Abdominal Infections in China

Clinical and Economic Impact of Methicillin-Resistant Staphylococcus Aureus: a Multicentre Study in China.

Effect of Multiple Drug Resistance on Total Medical Costs among Patients with Intra-Abdominal Infections in China.

SYSTEMATIC REVIEW OF THE ECONOMIC BURDEN OF ANTIBIOTIC RESISTANCE

PMU28 CLINICAL AND ECONOMIC OUTCOMES OF CARBAPENEM-RESISTANT GRAM-NEGATIVE ORGANISMS: A MULTICENTER STUDY IN CHINA

1808. Burden of infectious diseases and bacterial antimicrobial resistance in China, 2019: a systematic analysis

The Difference in Medical Costs Between Carbapenem-Resistant Acinetobacter Baumannii and Non-Resistant Groups: a Case Study from a Hospital in Zhejiang Province, China

Economic Burden of Community-Acquired Antibiotic-Resistant Urinary Tract Infections: Systematic Review and Meta-Analysis

Clinical and economic burden of bloodstream infections caused by meticillin-resistant and meticillin-susceptible Staphylococcus aureus in Chinese tertiary hospitals from 2010 to 2017: a multicentre, retrospective cohort study

PP118 the Value of New Antibiotic Treatment Strategies in Zhejiang Province, China

PMU82 EFFECT OF CARBAPENEM RESISTANCE ON TOTAL HOSPITALIZATION COSTS AMONG INPATIENTS WITH PSEUDOMONAS AERUGINOSA: A MULTICENTER STUDY IN CHINA

Clinical and Economic Impact of Third-Generation Cephalosporin-Resistant Infection or Colonization Caused by Escherichia Coli and Klebsiella Pneumoniae: A Multicenter Study in China

The impact of inpatient bloodstream infections caused by antibiotic-resistant bacteria in low- and middle-income countries: A systematic review and meta-analysis

Effectiveness of Educational Interventions for Health Workers on Antibiotic Prescribing in Outpatient Settings in China: A Systematic Review and Meta-Analysis

Direct Medical Burden of Antimicrobial-Resistant Healthcare-Associated Infections: Empirical Evidence from China

Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: A Multicenter Study in China

Burden of Infectious Diseases and Bacterial Antimicrobial Resistance in China: a Systematic Analysis for the Global Burden of Disease Study 2019

Direct economic burden and outcomes among patients with carbapenem-resistant acinetobacter baumannii infection or colonization

China-United States Research Collaborations in Antimicrobial Resistance.